Thursday, December 24, 2020 2:26:33 PM
BATON ROUGE, La., Dec. 16, 2020 /PRNewswire/ -- Prescience Point Capital Management, a research-focused, catalyst-driven investment firm, today announced it has issued new research on MiMedx Group Inc. (Nasdaq: MDXG), raising the price target on the leading advanced wound care and therapeutic biologics company to $31 per share. Prescience Point is one of the company's largest shareholders, owning 9 million or approximately 6.5% of the fully-diluted common stock of MiMedx.
Over the past six months, Prescience Point has conducted an in-depth analysis of MiMedx's Amniofix injectable product, which is currently in Phase 2b trials for knee osteoarthritis ("knee OA"), as well as Phase 3 trials for plantar fasciitis and Achillles tendonitis. Following the extensive analysis, which included a comprehensive review of the knee OA and osteoarthritis market, an analysis of clinical data, an analysis of competing treatment options, and conversations with dozens of physicians and patients who have used and been treated with the product, Prescience Point has concluded that Amniofix will be a game-changing treatment for knee OA and other musculoskeletal ailments, which will generate billions of dollars in annual sales for MiMedx.
Prescience Point's research indicates that Amniofix is a far superior treatment for knee OA than the few FDA approved treatments now available for the 20 million people in the U.S. who suffer from this chronic and debilitating condition. Prescience Point's research also indicates that Amniofix is a highly effective treatment for a variety of other musculoskeletal ailments including plantar fasciitis, shoulder osteoarthritis, and ankle osteoarthritis.
Based on the findings of its research, Prescience Point believes that the FDA will approve Amniofix for knee OA and multiple other indications beyond knee OA. Prescience Point also believes that the RMAT designation that the FDA granted to Amniofix could open the door for MiMedx to receive early approval after its Phase 2b knee OA trial, as the FDA can and often does approve fast track treatments following a successful Phase 2 trial.
"Although MiMedx's share price has increased by more than 200% since we published our initial report in January 2019, its shares are still trading at just a fraction of their fair value." said Eiad Asbahi, Founder and Managing Partner of Prescience Point. "We believe that MiMedx's wound care business by itself is worth at least $8 per share. This means that investors who purchase MiMedx shares today are buying the wound care business at a substantial discount and, on top of this, are receiving Amniofix, an asset that we believe is worth multi-billions of dollars, essentially for free."
Recent MDXG News
- MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- MIMEDX Introduces E-Commerce and Account Management Platform • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:28:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:27:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:27:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:11:28 PM
- MIMEDX Announces Appointment of Two New Independent Directors • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:22:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:02:35 PM
- MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 02/28/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:40:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:55:24 PM
- MIMEDX to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 09:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:22:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 08:11:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:13:13 PM
- MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28 • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:09:53 PM
- MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing • GlobeNewswire Inc. • 01/22/2024 01:00:00 PM
- MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook • GlobeNewswire Inc. • 12/29/2023 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:30 PM
- MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock • GlobeNewswire Inc. • 12/28/2023 01:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM